{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:52:48Z","timestamp":1791665568851,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":224,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium\u2013glucose cotransporter 2 inhibitors improve prognosis in chronic heart failure as part of currently recommended therapeutic strategies. Elevated levels of serum uric acid (SUA) have been associated with worsening of outcomes in cardiovascular disease and may lead to hyperuricaemia and gout as well as exacerbation of renal failure. The effects of empagliflozin on SUA in patients with acute decompensated heart failure (ADHF) remain unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In the single-centre, prospective, double-blind, placebo-controlled EMPAG-HF trial, patients with ADHF were screened and randomized within 12\u2009h following hospital admission to receive either empagliflozin or placebo in addition to standard medical treatment over 5\u2009days. Sixty patients were enrolled and randomized irrespective of left ventricular ejection fraction or diabetes. Serum and urine uric acid were evaluated as part of the standard monitoring protocol. Baseline patient characteristics did not differ between the two groups. SUA increased in the placebo group during diuretic therapy but decreased in the empagliflozin group. At 3, 4 and 5\u2009days, SUA was significantly lower in the empagliflozin group compared to placebo. The reduction in SUA following empagliflozin treatment was associated with an enhanced renal excretion of uric acid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Addition of empagliflozin to standard diuretic therapy may prevent the rise in SUA during decongestion in patients with ADHF and thus may prevent negative effects of hyperuricaemia including the occurrence of acute gout episodes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3723","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T14:31:14Z","timestamp":1752071474000},"page":"1472-1478","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of Empagliflozin on Uric Acid Levels During Acute Heart Failure Recompensation: A Sub-Analysis of the EMPAG-HF Trial (Effects of Empagliflozin on Diuresis and Renal Function in Patients with Acute Decompensated Heart Failure)"],"prefix":"10.1093","volume":"27","author":[{"given":"Jurgen","family":"Bogoviku","sequence":"first","affiliation":[{"name":"Division of Cardiology, Angiology and Intensive Medical Care, Department of Internal Medicine I, University Hospital Jena , Jena ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien Dung","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Angiology and Intensive Medical Care, Department of Internal Medicine I, University Hospital Jena , Jena ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian Georg","family":"Westphal","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Angiology and Intensive Medical Care, Department of Internal Medicine I, University Hospital Jena , Jena ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Haertel","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Angiology and Intensive Medical Care, Department of Internal Medicine I, University Hospital Jena , Jena ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Aftanski","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Angiology and Intensive Medical Care, Department of Internal Medicine I, University Hospital Jena , Jena ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"M\u00f6bius-Winkler","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Angiology and Intensive Medical Care, Department of Internal Medicine I, University Hospital Jena , Jena ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Busch","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine III, University Hospital Jena , Jena ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Christian","family":"Schulze","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Angiology and Intensive Medical Care, Department of Internal Medicine I, University Hospital Jena , Jena ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"2026021721460443900_ejhf3723-bib-0001","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2026021721460443900_ejhf3723-bib-0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: Preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail"},{"key":"2026021721460443900_ejhf3723-bib-0003","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026021721460443900_ejhf3723-bib-0004","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen17X101013","article-title":"Prognosis following a diagnosis of heart failure and the role of primary care: A review of the literature","volume":"1","author":"Jones","year":"2017","journal-title":"BJGP Open"},{"key":"2026021721460443900_ejhf3723-bib-0005","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/ehf2.13296","article-title":"Recurrent heart failure hospitalizations increase the risk of cardiovascular and all-cause mortality in patients with heart failure in Sweden: A real-world study","volume":"8","author":"Lindmark","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026021721460443900_ejhf3723-bib-0006","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026021721460443900_ejhf3723-bib-0007","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10741-019-09869-z","article-title":"Hyperuricemia: A novel old disorder-relationship and potential mechanisms in heart failure","volume":"25","author":"Borghi","year":"2020","journal-title":"Heart Fail Rev"},{"key":"2026021721460443900_ejhf3723-bib-0008","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","article-title":"Uric acid and risk of heart failure: A systematic review and meta-analysis","volume":"16","author":"Huang","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026021721460443900_ejhf3723-bib-0009","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.CIR.0000017502.58595.ED","article-title":"Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: Results from 2 placebo-controlled studies","volume":"105","author":"Doehner","year":"2002","journal-title":"Circulation"},{"key":"2026021721460443900_ejhf3723-bib-0010","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.amjcard.2016.02.039","article-title":"Prognostic significance of hyperuricemia in patients with acute heart failure","volume":"117","author":"Palazzuoli","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026021721460443900_ejhf3723-bib-0011","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"2026021721460443900_ejhf3723-bib-0012","article-title":"Hyperuricemia complicated with acute kidney injury is associated with adverse outcomes in patients with severely decompensated acute heart failure","volume":"23","author":"Shirakabe","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026021721460443900_ejhf3723-bib-0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114058","article-title":"Diuretic resistance in patients with kidney disease: Challenges and opportunities","volume":"157","author":"Guo","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2026021721460443900_ejhf3723-bib-0014","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021721460443900_ejhf3723-bib-0015","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021721460443900_ejhf3723-bib-0016","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1038\/s41598-023-32072-y","article-title":"The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD","volume":"13","author":"Iwata","year":"2023","journal-title":"Sci Rep"},{"key":"2026021721460443900_ejhf3723-bib-0017","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"key":"2026021721460443900_ejhf3723-bib-0018","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cardfail.2020.08.015","article-title":"Uric acid is a biomarker of oxidative stress in the failing heart: Lessons learned from trials with allopurinol and SGLT2 inhibitors","volume":"26","author":"Packer","year":"2020","journal-title":"J Card Fail"},{"key":"2026021721460443900_ejhf3723-bib-0019","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cpt197925133","article-title":"Hydrochlorothiazide and spironolactone in hypertension","volume":"25","author":"Schrijver","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"2026021721460443900_ejhf3723-bib-0020","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: The EMPEROR-Reduced trial","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021721460443900_ejhf3723-bib-0021","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jare.2016.11.004","article-title":"Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review","volume":"8","author":"Sharaf El Din","year":"2017","journal-title":"J Adv Res"},{"key":"2026021721460443900_ejhf3723-bib-0022","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/BF03401822","article-title":"Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy","volume":"6","author":"Kim","year":"2000","journal-title":"Mol Med"},{"key":"2026021721460443900_ejhf3723-bib-0023","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000443283","article-title":"Effects of serum uric acid on estimated GFR in cardiac surgery patients: A pilot study","volume":"42","author":"Ejaz","year":"2015","journal-title":"Am J Nephrol"},{"key":"2026021721460443900_ejhf3723-bib-0024","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/301021","article-title":"Hyperuricemia: An early marker for severity of illness in sepsis","volume":"2015","author":"Akbar","year":"2015","journal-title":"Int J Nephrol"},{"key":"2026021721460443900_ejhf3723-bib-0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/ckj\/sfv086","article-title":"Admission hyperuricemia increases the risk of acute kidney injury in hospitalized patients(.)","volume":"9","author":"Cheungpasitporn","year":"2016","journal-title":"Clin Kidney J"},{"key":"2026021721460443900_ejhf3723-bib-0026","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2215\/CJN.05870614","article-title":"Plasma urate and risk of a hospital stay with AKI: The Atherosclerosis Risk in Communities study","volume":"10","author":"Greenberg","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026021721460443900_ejhf3723-bib-0027","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13098-020-00545-z","article-title":"The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease","volume":"12","author":"Ohara","year":"2020","journal-title":"Diabetol Metab Syndr"},{"key":"2026021721460443900_ejhf3723-bib-0028","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"2026021721460443900_ejhf3723-bib-0029","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021721460443900_ejhf3723-bib-0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.33315","article-title":"Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: The Atherosclerosis Risk in Communities cohort study","volume":"64","author":"McAdams DeMarco","year":"2012","journal-title":"Arthritis Rheum"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/8\/1472\/66813352\/eurjhf_27_8_1472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/8\/1472\/66813352\/eurjhf_27_8_1472.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:46:20Z","timestamp":1771382780000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/8\/1472\/8468079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,7,9]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3723","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"2024-09-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}